Business / Finance

RSS

Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Resverlogix Corp. today announced that it has entered into a Framework Agreement which sets forth the principal business terms for an equity investment and a license of RVX-208, for all indications, to Shenzhen Hepalink Pharmaceutical Co., Ltd. for China, Hong Kong, Taiwan and Macau (the "Territories").

27 Apr 2015

Neuronetics completes Series F Financing Round

Neuronetics, Inc., the established market leader in transcranial magnetic stimulation (TMS) technology, announced today the completion of its Series F Financing Round, which included investment from GE Ventures, as well as its original investor base totaling $34.3 million.

27 Apr 2015

American Securities signs agreement to acquire Royal Adhesives and Sealants

American Securities LLC and Arsenal Capital Partners today announced that American Securities has partnered with management and signed a definitive agreement to acquire Royal Adhesives and Sealants, LLC, a leading producer of proprietary, high-performance adhesives and sealants, from Arsenal Capital Partners.

27 Apr 2015

Haemonetics' revenue for fourth quarter fiscal 2015 down 6%

Haemonetics Corporation today reported revenue for the fourth quarter fiscal 2015 of $226.5 million, down 6%. Excluding currency impact, revenue was down 4% in the quarter. The Company reported a fourth quarter GAAP net loss of $2.9 million or $0.06 per share.

27 Apr 2015

TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant

TWi Pharmaceuticals, Inc. today announced that it has entered into a Settlement Agreement with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals America, Inc. (individually and collectively, "Takeda") to settle and dismiss all outstanding patent litigation related to TWi's generic dexlansoprazole delayed release capsules for oral administration in 30 mg and 60 mg dosage strengths.

27 Apr 2015

OncoGenex terminates agreement with Teva, regains rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva Pharmaceuticals Ltd. under which OncoGenex will regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers.

27 Apr 2015

Natera, LifeLabs sign new agreement for non-invasive prenatal testing in Canada

Natera, Inc., a global leader in non-invasive genetic testing, and LifeLabs Medical Laboratory Services today announced a new agreement that gives LifeLabs the rights to perform non-invasive prenatal testing (NIPT) in Canada using Natera technology.

From Natera 25 Apr 2015

Lannett amends, increases revolving credit facility from $50 million to $120 million

Lannett Company, Inc. today announced that it has amended and increased its five-year revolving credit facility to $120 million from $50 million. The amended facility includes an accordion feature that will allow the company to increase borrowings by a total of up to an additional $30.0 million, subject to securing additional commitments from existing lenders or new lending institutions.

24 Apr 2015

DATIS, NPS MedicineWise partner to deliver face-to-face educational visits to GPs across South Australia

A new three-year contract launched in Adelaide today will see the Drug and Therapeutics Information Service based at the Repatriation General Hospital continue to deliver NPS MedicineWise educational visiting programs to general practitioners (GPs) across South Australia.

24 Apr 2015

DATIS, NPS MedicineWise partner to deliver face-to-face educational visits to GPs across South Australia

A new three-year contract launched in Adelaide today will see the Drug and Therapeutics Information Service (DATIS) based at the Repatriation General Hospital continue to deliver NPS MedicineWise educational visiting programs to general practitioners (GPs) across South Australia.

24 Apr 2015

Eppendorf launches mobile app

Eppendorf AG's new app offers a variety of useful aids for everyday laboratory work in addition to product information that has been optimized for mobile devices.

24 Apr 2015

ELC Group signs landmark deal with Chinese pharmaceutical giant

ELC Group, one of the fastest-growing providers of regulatory affairs services, today announces that it has been awarded a 1.5 million Euro contract by one of China’s biggest pharmaceutical companies.

24 Apr 2015

Getinge secures EUR 160 million loan from EIB for development of new medical devices

The European Investment Bank has provided a EUR 160 million loan to Getinge AB, a global medical technology company, for its research and development in the areas of surgery, intensive care, infection control, care ergonomics and wound care. Getinge’s research addresses unmet medical needs and targets the development of new devices with higher efficiency and safety for increased positive outcomes for both caregivers and patients.

24 Apr 2015

Yorkshire & Humber Academic Health Science Network (AHSN) hosts Medicines Optimisation Roadshow on Tuesday 12 May 2015

The Yorkshire The Yorkshire & Humber Academic Health Science Network (AHSN) will be hosting their Medicines Optimisation Roadshow on Tuesday 12 May 2015.

23 Apr 2015

Alltech enters into agreement to acquire Ridley

Alltech and Ridley Inc. announced today that they have entered into a plan of arrangement agreement under which Alltech will acquire 100 percent of the outstanding stock of Ridley, one of the leading commercial animal nutrition companies in North America, for CAD $40.75 per share.

23 Apr 2015

Metanome changes name to Diversigen

Metanome, Inc., an industry leader in comprehensive microbiome services, today announced the company has changed its name to Diversigen, Inc. The name was changed to reflect Diversigen's positioning as the single commercial source for the myriad of services and expertise customers need to capitalize on the diverse opportunities of the microbiome.

23 Apr 2015

Quest Diagnostics' revenues grow 5.3% to $1.84 billion in first quarter 2015

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced today that for the first quarter ended March 31, 2015, adjusted net income was $141 million, compared to $122 million in 2014. Adjusted diluted EPS excluding amortization was $1.05 in the quarter, compared to $0.93 in 2014. Amortization expense was $0.09 per diluted share in both years.

From Quest Diagnostics 23 Apr 2015

IDT’s San Diego, California, manufacturing facility receives ISO 14001 certification

Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, has announced that its San Diego, California, manufacturing facility has attained ISO 14001:2004 certification for its environmental management systems. Now, both of IDT’s US manufacturing sites (Coralville, IA and San Diego, CA) have ISO 14001 certified environmental management systems.

From Integrated DNA Technologies 22 Apr 2015

Sysmex Inostics to offer OncoBEAM CLIA laboratory services in Germany, Austria and Switzerland

Sysmex Inostics, a subsidiary of Sysmex Corporation, today announced that they have signed an exclusive distributor agreement with IndivuTest GmbH, and its parent company Indivumed GmbH, a cancer research company focused on the development of individualized cancer diagnostics and therapies.

From Sysmex America, Inc. 22 Apr 2015

Astellas, Potenza collaborate to develop immuno-oncology therapeutics for patients with certain cancers

Astellas Pharma Inc. and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today announced an exclusive research and development collaboration.

22 Apr 2015

Business / Finance

Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Neuronetics completes Series F Financing Round

American Securities signs agreement to acquire Royal Adhesives and Sealants

Haemonetics' revenue for fourth quarter fiscal 2015 down 6%

TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant

OncoGenex terminates agreement with Teva, regains rights to custirsen

Natera, LifeLabs sign new agreement for non-invasive prenatal testing in Canada

Lannett amends, increases revolving credit facility from $50 million to $120 million

DATIS, NPS MedicineWise partner to deliver face-to-face educational visits to GPs across South Australia

DATIS, NPS MedicineWise partner to deliver face-to-face educational visits to GPs across South Australia

Eppendorf launches mobile app

ELC Group signs landmark deal with Chinese pharmaceutical giant

Getinge secures EUR 160 million loan from EIB for development of new medical devices

Yorkshire & Humber Academic Health Science Network (AHSN) hosts Medicines Optimisation Roadshow on Tuesday 12 May 2015

Alltech enters into agreement to acquire Ridley

Metanome changes name to Diversigen

Quest Diagnostics' revenues grow 5.3% to $1.84 billion in first quarter 2015

IDT’s San Diego, California, manufacturing facility receives ISO 14001 certification

Sysmex Inostics to offer OncoBEAM CLIA laboratory services in Germany, Austria and Switzerland

Astellas, Potenza collaborate to develop immuno-oncology therapeutics for patients with certain cancers

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News